Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Natural killer group 2 member D ligand family comprises a set of stress-inducible cell surface proteins that serve as key recognition molecules for innate immunity. In humans, this family includes two major groups: MHC class I polypeptide-related sequence A/B (MICA/MICB) proteins and UL16-binding proteins (ULBP1–6), also known as retinoic acid early transcript 1 (RAET1) proteins. These ligands are normally expressed at low levels but are upregulated during cellular stress—such as infection by viruses/bacteria or malignant transformation—and act as "danger signals" that alert cytotoxic lymphocytes expressing the activating receptor NKG2D. Upon binding these ligands on stressed cells—including infected cells and many types of tumors—the NKG2D receptor triggers activation signals in natural killer cells and certain T-cell subsets such as CD8+ αβ T cells and γδ T cells. This leads to targeted killing through release of cytotoxic granules containing perforin/granzymes along with cytokine secretion amplifying overall immunity. Polymorphisms within MICA/MICB genes affect their affinity for binding receptors like NKG2D which has implications not only in cancer immunosurveillance but also organ transplantation compatibility where mismatches may increase rejection risks. Soluble forms shed from tumor surfaces can suppress anti-tumor immunity by downregulating surface expression while circulating forms may serve diagnostic/prognostic markers reflecting disease status especially cancers like colon adenocarcinoma where differential gene expressions correlate with clinical outcomes.[3][5][7]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Natural killer group 2 member D ligand family (NKG2DL).